Bibliographie
ABRAMKIN S.A. et al. (2010) : (1R,2R,4R)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo, J. Med. Chem., 53, 7356–7364.
ALBERTO M.E. et al. (2008) : The Degradation Pathways in Chloride Medium of the Third Generation Anticancer Drug Oxaliplatin. Journal of Physical Chemistry B, 112, 10765-10768.
ARNESANO F. et al. (2015) : Effect of chirality in platinum drugs Coordination Chemistry Reviews, 284, 286–297
BOWDEN N.A (2014) : Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Letters, 346, 163–171
CASINI A., REEDIJK J. (2012) : Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry? Chemical Science, 3, 3135-3144.
CHATELUT E. (2011) : Pharmacologie des dérivés du platine : différences entre les trois composés et les facteurs de variabilité entre patients. Bulletin du Cancer, 98, 1253-1261.
CHIRINO Y.I., PEDRAZA-CHAVERRI J (2009) : Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity Experimental and Toxicologic Pathology, 61, 223–242
CRIDER S.E. et al. (2010) : Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1, Metallomics, 2, 74-83.
DI PASQUA A.J. et al. (2011) : Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association Dalton Transactions, 40, 4821-4825.
DU X. et al. (2012) : Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1) Metallomics, 4, 679-685.
ELJACK N.D. et al. (2014) : Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics, 6, 2126-2133.
ERXLEBEN A. et al. (2002) : Model of the most abundant DNA interstrand cross-link of Transplatin: X-ray structures of two modifications and H bonding behavior in the solid state and in solution of trans-[Pt(NH3)2(1-MeC-N3)(9-EtGH-N7)](ClO4)2 ×/nH2O (1-MeC/1-methylcytosine; 9-EtGH/9-ethylguanine), Inorganica Chimica Acta, 339, 461-469.
FERRARO G. et al. (2015) : Cisplatin binding to human serum albumin: a structural study. Chemical Communications, 51, 9436-9439.
JERREMALM E. et al. (2004) : Oxaliplatin Degradation in the Presence of Chloride: Identification and Cytotoxicity of the Monochloro Monooxalato Complex Pharmaceutical Research, 21, 891-894.
JOHNSTONE T.C (2014) : The crystal structure of oxaliplatin: A case of overlooked pseudo symmetry Polyhedron, 67, 429–435
KRUGER K. et al. (2015) : Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury Biochimica et Biophysica Acta, 1853, 685–698.
LORD C.J., ASHWORTH A. (2012) : The DNA damage response and cancer therapy, Nature, 481, 287-294.
LUCAS M.F.A. et al. (2009) : Neutral and Acidic Hydrolysis Reactions of the Third Generation Anticancer Drug Oxaliplatin. Journal of Physical Chemistry B, 113, 831-838.
MONNERET C. (2011) : Platinum anticancer drugs. From serendipity to rational design Annales Pharmaceutiques Françaises, 69, 286-295.
NEIDLE S. et al. (1980) : The Structure of the Antitumor Complex Cis-(diammino) (1,1-cyclobutanedicarboxylato)- Pt(II): X Ray and NMR Studies Journal of Inorganic Biochemistry, 13, 205-212.
PARK S., LIPPARD S.J. (2012) : Binding Interaction of HMGB4 with Cisplatin Modified DNA Biochemistry, 51, 6728-6737.
POURQUIER P., ROBERT J. (2011) : Présentation générale des mécanismes de réparation de l'ADN Bulletin du Cancer, 98, 229-237.
ROSENBERG B, van CAMP L, KRIGAS T. (1965) : Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode, Nature, 205, 698-699.
SHARMA S. et al. (2007) : Molecular Dynamic Simulations of Cisplatin- and Oxaliplatin-d(GG) Intrastand Cross-links Reveal Differences in their Conformational Dynamics, J. Mol. Biol., 373, 1123-1140
SOORI H. et al. (2015) : Exploring binding affinity of oxaliplatin and carboplatin, to nucleoprotein structure of chromatin: Spectroscopic study and histone proteins as a target. European Journal of Medicinal Chemistry, 89, 844-850
TODD R.C., LIPPARD S.J. (2009) : Inhibition of transcription by platinum antitumor compounds Metallomics, 1, 280–291.
TODD R.C., LIPPARD S.J. (2010) : Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77 A resolution, Journal of Inorganic Biochemistry, 104, 902–908.
WANG E. et al. (2013) : Interaction between Platinum Complexes and the C‐Terminal Motif of Human Copper Transporter 1, Inorganic Chemistry, 52, 6153-6159.
YONEZAWA A., INUI K.I. (2011) : Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents, Biochemical Pharmacology, 81, 563-568.
